| Date | Wednesday, August 12 | Thursday, August 13 | Friday, August 14 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Room | VISTA 1 | VISTA 2 | Grand Hall 1 | Walker Hall 1 | Walker Hall 2 | VISTA 1 | VISTA 2 | Grand Hall 1 | Walker Hall 1 | Walker Hall 2 | Grand Hall 2 | VISTA 1 | VISTA 2 | Grand Hall 1 | Walker Hall 1 |
| 7:30-8:00 | Business Meeting (Walker Hall 1) | ||||||||||||||
| 8:00-8:30 | Registration | Registration | Registration | ||||||||||||
| 8:30-9:00 | Opening Remark (8:50-9:00) | Working party Report | |||||||||||||
| 9:00-10:30 | [JS01] KAI-KSH Joint Session |
[JS03] EHA-KSH Joint Symposium I - Basic |
[SS06] Benign Hematology |
[ES03] Multiple Myeloma |
[JS04] EHA-KSH Joint Symposium II |
[SS10] Pediatric Disease |
[SS11] T-cell Lymphoma/ HD |
||||||||
| 10:30-10:45 | Break | Break | Break | ||||||||||||
| 10:45-11:45 | [PL01] Cutting Edge of Emerging Therapies |
[PL02] Clinical Hematology Lecture |
[PL03] Genomics in Hematologic Malignancies |
||||||||||||
| 11:45-12:45 | [PS01] Presidential Symposium |
[MS01] MOU Countries Session |
Poster Sesion | Award Ceremony & Closing (11:45-12:30) |
|||||||||||
| 12:45-13:40 | [LS01] Amgen |
[LS02] Sanofi-Aventis |
[LS03] BMS |
[LS04] Kyowa Kirin |
[LS05] Takeda |
[LS06] Celgene |
[LS07] Handok |
[LS08] Roche |
[LS09] Novartis |
[LS10] Janssen |
|||||
| 13:40-14:55 | [AS01] Asian Hematology Session 1 |
[AS02] Asian Hematology Session 2 |
Break (13:40-14:10) | ||||||||||||
| Oral Session I (14:10-15:10) | |||||||||||||||
| Break (14:40-14:55) | |||||||||||||||
| 14:55-16:25 | [JS02] KOGO-KSH Joint Session - Genomics for Precision Hematology |
[SS01] Acute Lymphoblastic Leukemia |
[SS02] B-cell Lymphoma |
[ES01] Acute Myeloid Leukemia |
Break (15:10-15:25) | ||||||||||
Oral Session II (15:25-16:25) |
|||||||||||||||
| 16:25-16:40 | Break | Break | |||||||||||||
| 16:40-18:10 | [SS03] Multiple Myeloma |
[SS04] Advances in Technology |
[SS05] Stem Cell: Biology and Therapeutic Target |
[ES02] Acute Lymphoblastic Leukemia |
[SS07] Bone Marrow Failure Syndrome |
[SS08] Supportive Care |
[SS09] Cell Therapy / Transplantation |
[ES04] Lymphoma |
|||||||
| 18:10-18:30 | |||||||||||||||
| 18:30-20:00 | Welcome Reception | Gala Dinner | |||||||||||||
| Room | VISTA 1 | VISTA 2 | Grand Hall 1 | Walker Hall 1 | Walker Hall 2 |
|---|---|---|---|---|---|
| 08:00-09:00 | Registration | ||||
| 08:50-09:00 | Opening | ||||
| 9:00-10:30 | [JS01] KAI-KSH Joint Session - Immunotherapeutics in Blood Disease |
||||
| Role of PD-1 on Regulatory T Cells in Modulating Immunity during Cancer Progression Sang-Jun Ha, Korea |
|||||
| Regulation of Anti-Tumor Immunity by IL-17-producing T Cells Yeon Seok Chung, Korea |
|||||
| Pro-Inflammatory Cytokines in Graft-Versus-Host Disease (GVHD) Youngwoo Jeon, Korea |
|||||
| Dendritic Cell-Based Therapeutic Approaches for Treatment of Multiple Myeloma Manh-Cuong Vo, Vietnam |
|||||
| 10:30-10:45 | Coffee Break | ||||
| 10:45-11:45 | Plenary Lecture I - Cutting Edge of Emerging Therapies | ||||
| T Cell Immunotherapy via Native and Chimeric Receptors Helen Heslop, USA |
|||||
| 11:45-12:45 | Presidential Symposium | ||||
| The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment Elizabeth Macintyre, France |
|||||
| 12:45-13:40 | [LS01] Luncheon Symposium | [LS02] Luncheon Symposium | [LS03] Luncheon Symposium | [LS04] Luncheon Symposium | [LS05] Luncheon Symposium |
| 13:40-14:40 | [AS01] Cutting Edge Therapeutic Approaches in CML | [AS02] Updates of Hematologic Disease in Asian Population | |||
| From Korean Perspective Young Rok Do, Korea |
Management of TDT and NTDT Thalassemia in Indonesia Tubagus Djumhana Atmakusuma, Indonesia |
||||
| From Chinese Perspective Qian Jiang, China |
Hemophilia Treatment in Singapore Tien Sim Leng, Singapore |
||||
| From Japanese Perspective Shinya Kimura, Japan |
Thalassemia Treatment in Malaysia Jameela Sathar, Malaysia |
||||
| 14:55-16:25 | [JS02] KOGO-KSH Joint Session - Genomics for Precision Hematology |
[SS01] Acute Lymphoblastic Leukemia | [SS02] B-cell Lymphoma | [ES01] Acute Myeloid Leukemia | |
| Transcriptional Programs Associated with Aggressive Myeloma Progression Hae-Ock Lee, Korea |
Contemporary Treatment of Pediatric Ph+ ALL Kirk Schultz, Canada |
Genomic Landscape of DLBCL Laura Pasqualucci, USA |
Classification of AML Sang Mee Hwang, Korea |
||
| DNA Methylation Landscape and Intra-Tumor Heterogeneity in Cancer Sun kim, Korea |
Current Treatment Approaches to Newly Diagnosed Adult ALL Daniel J. DeAngelo, USA |
Immunotherapy for Hodgkin's Lymphoma John Kuruvilla, Canada |
Treatment of Children and Adolescents with AML Hyery Kim,Korea |
||
| Clinical Application of Next-Generation Sequencing in Acute Myeloid Leukemia Jae-Sook Ahn, Korea TBD TBD, Korea |
Results of High Risk and Novel Subtypes of Pediatric ALL in Japan Katsuyoshi Koh, Japan |
Optimal Treatment of High Risk Aggressive B Cell Lymphoma Lorenz Trumper, Germany |
New Agents in AML Silvia Park, Korea |
||
| 16:25-16:40 | Break | ||||
| 16:40-18:10 | [SS03] Multiple Myeloma | [SS04] Advances in Technology | [SS05] Stem Cell: Biology and Therapeutic Target |
[ES02] Acute Lymphoblastic Leukemia | |
| Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma Suzanne Trudel, Canada | HARMONY: A Big Data for Better Outcomes Project in Hematological Malignancies Jesús María Hernández Rivas, Spain |
Microenvironmental Control of Hematopoietic Regeneration Lev Silberstein, USA |
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical Aspects and Implications for Clinical Interpretation In-Suk Kim, Korea |
||
| MRD Negativity - The Foremost Important Goal of Myeloma Treatment? Bruno Paiva, Spain |
Intelligent Image-Activated Cell Sorting: Principles and Application to Hematology Akihiro Isozaki, Japan |
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia Ninib Baryawno, Sweden |
Optimal Therapy for Adolescents and Young Adults with Acute Lymphoblastic Leukemia-Current Perspectives Jae Wook Lee, Korea |
||
| Primary Amyloidosis Ki Hyun Kim, Korea |
Incorporating Genetics into Clinic Elli Papaemmanuil, USA |
BCL-2 as a Stem Cell Target in AML Daniel A. Pollyea, USA |
Current Treatment Strategies for Philadelphia Chromosome-Positive Adult ALL Han-Seung Park, Korea |
||
| 18:10-18:30 | Break | ||||
| 18:30-20:00 | Welcome Reception | ||||
| Room | VISTA 1 | VISTA 2 | Grand Hall 1 | Walker Hall 1 | Walker Hall 2 | Grand Hall 2 | |
|---|---|---|---|---|---|---|---|
| 08:00-09:00 | Registration | ||||||
| 9:00-10:30 | [JS03] EHA-KSH Joint Symposium I - Basic |
[SS06] Benign Hematology | [ES03] Multiple Myeloma | ||||
| The Evil Side of Gene Regulation in AML TBD |
Novel Treatment for ITP Cindy Neunert, USA |
Frontline Therapy for Newly Diagnosed Multiple Myeloma Jae-Cheol Jo, Korea |
|||||
| TET Loss-of-Function in Malignant Hematopoiesis Myunggon Ko, Korea |
|||||||
| Clonal Evolution under IDH Inhibitor Therapy in Acute Myeloid Leukaemia Lynn Quek, UK |
Recent Understandings of Congenital Neutropenia TBD |
Treatment of Relapsed/Refractory Multiple Myeloma Ji Hyun Lee, Korea |
|||||
| NRAS Mutant AML Taebo Sim, Korea |
Post-Transplant Thrombotic Microangiopathy Vahid Afshar-Kharghan, USA |
AL Amyloidosis: Advance in Diagnosis and Management Youngil Koh, Korea |
|||||
| 10:30-10:45 | Coffee Break | ||||||
| 10:45-11:45 | Plenary Lecture II - Clinical Hematology Lecture | ||||||
| Genetic Landscape of Lymphoma and Novel Treatment Approaches Wyndham Hopkins Wilson, USA |
|||||||
| 11:45-12:45 | [MS01] MOU Country Session 1 | Poster Presentation | |||||
| Outcome of Autologous Transplant in T Cell Lymphoma: Experience of NIHBT in Vietnam Nguyen Vu Bao Anh, Vietnam |
|||||||
| Subcutaneous Panniculitis-like T-cell Lymphoma Udomsak Bunworasate, Thailand |
|||||||
| Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology Seok Jin Kim, Korea |
|||||||
| 12:45-13:40 | [LS06] Luncheon Symposium | [LS07] Luncheon Symposium | [LS08] Luncheon Symposium | [LS09] Luncheon Symposium | [LS10] Luncheon Symposium | ||
| 13:40-14:10 | Break | ||||||
| 14:10-15:10 | ORAL I | ||||||
| 15:10-15:25 | Break | ||||||
| 15:25-16:25 | ORAL II | ||||||
| 16:25-16:40 | Break | ||||||
| 16:40-18:10 | [SS07] Bone Marrow Failure Syndrome | [SS08] Supportive Care | [SS09] Cell Therapy/Transplantation | [ES04] Lymphoma | |||
| Challenges in the Diagnosis of Bone Marrow Failure Syndromes: The Role of Genetic Panels? Ghulam J Mufti, UK |
Improve Palliative Care and Outcomes in Low- and Middle-Income Countries Scott Howard, USA |
CAR T for AML: Developing AML-Specific Anti-CD33 CAR T Cells by Gene Editing Saar Gill, USA |
Primary CNS Lymphoma Yoon Seok Choi, Korea |
||||
| Clonal Hematopoesis in Bone Marrow Failure Daria V. Babushok, USA |
Chemotherapy-Induced Peripheral Neuropathy in Patients with Hematologic Malignancies TBD |
Immune Escape and Relapse after Allogeneic Hematopoietic Cell Transplantation Luca Vago, Italy |
Extranodal NK/T Cell Lymphoma Seong Hyun Jeong, Korea |
||||
| The Current Treatment Algorithm for Patients with Acquired Aplastic Anemia in Japan Shinji Nakao, Japan |
Vaccinations before/after Biologic Agents in Patients with Hematologic Malignancies TBD | HSCT: Alloreactivity in Haploidentical Stem Cell Transplantation with Post-Cy TBD |
Recent Advances in CLL Therapy Jieun Uhm, Korea |
||||
| 18:10-18:30 | |||||||
| 18:30-20:00 | Gala Dinner | ||||||
| Room | VISTA 1 | VISTA 2 | Grand Hall 1 | Walker Hall 1 | Walker Hall 2 |
|---|---|---|---|---|---|
| 07:30-08:30 | Business Meeting | ||||
| 08:30-09:00 | Working Party Reports | ||||
| 09:00-10:30 | [JS04] EHA-KSH Joint Symposium II - Clinical Translational |
[SS10] Pediatric Disease | [SS11] T-Cell Lymphoma /HD | ||
| BiTing Leukemia: T Cell Recruiting Antibody Constructs for Treatment of AML TBD |
Juvenile Myelomonocytic Leukemia: Learning from Patients in a World Without Walls Mignon Loh, USA |
PD-L1 and NK/T-Cell Lymphoma Won Seog Kim, Korea |
|||
| Therapeutic Potential of Ascorbic Acid in TET2-Mutated AML Junshik Hong, Korea |
|||||
| The Emerging Role of MRD in AML Gert Ossenkoppele, The Netherlands |
The Role of RAS Mutation in Relapsed ALL Julie Irving, UK |
Novel Agents for PTCL Francine Foss, USA |
|||
| MRD in AML Byung Sik Cho, Korea |
Langerhans Cell Histiocytosis 2020: New Insights and Opportunities Carl Allen, USA |
A Translational Research in Angioimmunoblastic T-Cell Lymphoma: From Genome to Bedside Mamiko Sakata-Yanagimoto, Japan |
|||
| 10:30-10:45 | Coffee Break | ||||
| 10:45-11:45 | Plenary Lecture III - Genomics in Hematologic Malignancies | ||||
| Latest Treatment Developments in Multiple Myeloma Nikhil Munshi, USA |
|||||
| Genetic Alterations in Relapsed/Refractory AML: Is There Something Special? Hyeoung-Joon Kim, Korea |
|||||
| 11:45-12:30 | Award Ceremony & Closing | ||||
